Alnylam Pharmaceuticals I... (ALNY)
237.68
11.40 (5.04%)
At close: Apr 11, 2025, 3:59 PM
230.08
-3.19%
After-hours: Apr 11, 2025, 05:51 PM EDT
5.04% (1D)
| Bid | 220.85 |
| Market Cap | 30.92B |
| Revenue (ttm) | 2.25B |
| Net Income (ttm) | -278.16M |
| EPS (ttm) | -2.19 |
| PE Ratio (ttm) | -108.53 |
| Forward PE | 441.36 |
| Analyst | Buy |
| Ask | 238.89 |
| Volume | 1,347,407 |
| Avg. Volume (20D) | 887,870 |
| Open | 223.31 |
| Previous Close | 226.28 |
| Day's Range | 223.41 - 240.00 |
| 52-Week Range | 141.98 - 304.39 |
| Beta | 0.30 |
About ALNY
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection f...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 1, 2004
Employees 2,230
Stock Exchange NASDAQ
Ticker Symbol ALNY
Website https://www.alnylam.com
Analyst Forecast
According to 24 analyst ratings, the average rating for ALNY stock is "Buy." The 12-month stock price forecast is $322.5, which is an increase of 35.69% from the latest price.
Stock ForecastsNext Earnings Release
Alnylam Pharmaceuticals Inc. is scheduled to release its earnings on May 1, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
+2.6%
Alnylam Pharmaceuticals shares are trading higher ...
Unlock content with
Pro Subscription
3 weeks ago
+11.75%
Alnylam Pharmaceuticals shares are trading higher after the company secured FDA approval pf sNDA for its RNAi therapeutic, AMVUTTRA ,for treatment of ATTR-CM in adults.
